Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Terpenoid+1 more
Cannabinoid systemTetrahydrocannabinol
THC (delta-9-tetrahydrocannabinol) — weed, pot, marijuana — is a cannabinoid of the terpenophenolic class. It is the principal psychoactive compound in Cannabis sativa, the most widely consumed illicit plant in history. It activates cannabinoid receptors in the brain, suppressing neurotransmitter release and producing its characteristic shifts in mood, perception, and memory.
THC (delta-9-tetrahydrocannabinol) is a naturally-occurring cannabinoid of the terpenophenolic class. It is the principal psychoactive constituent of Cannabis sativa, the most widely consumed illicit plant in history. THC is a partial agonist at CB1 cannabinoid receptors,[1] producing its effects by suppressing neurotransmitter release through the brain's retrograde endocannabinoid signalling system.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Terpenoid+1 more
Cannabinoid systemCannabis has been used therapeutically for millennia, but THC itself wasn't identified until 1964, when Gaoni and Mechoulam isolated and characterized it.[1] That discovery led to the identification of the endocannabinoid system — an entirely new signalling network in the brain.[2][3] As of 2026, recreational cannabis is legal in Canada, Germany, and many US states, and FDA-approved THC formulations sit in US Schedule III.[4]
Subjective effects include euphoria, appetite stimulation, time alteration, relaxation, and anxiety at higher doses. The experience is defined by its sensitivity to context — the same dose can produce warm calm in one setting and anxious self-consciousness in another.[5] Paranoia, short-term memory disruption, and brief psychotic-like symptoms are characteristic unwanted effects.[6]
About 9% of users develop cannabis use disorder, rising to 17% in adolescence;[7] no confirmed human fatality from overdose alone has been recorded.[8][9] The primary danger is psychiatric — daily high-potency use carries an odds ratio of 4.8 for psychotic disorder,[10] amplified by early onset and genetic vulnerability. Six decades of research make THC one of the most thoroughly characterized psychoactive compounds known.
History[edit]
Discovery
Cannabis has been used medicinally for millennia — documented in ancient Vedic texts, Chinese pharmacopoeia, and Egyptian medical papyri.[11][12] The identity of the psychoactive compound eluded science until 1964, when Yechiel Gaoni and Raphael Mechoulam published the isolation and structural characterization of delta-9-tetrahydrocannabinol.[1] That single paper founded modern cannabinoid pharmacology.
The endocannabinoid system
THC's isolation set off one of the most productive research programmes in neuroscience. In 1988, a specific cannabinoid binding site was identified in rat brain;[2] later mapping revealed dense receptor expression in the hippocampus, basal ganglia, cerebellum, and cortex — with sparse brainstem presence, directly explaining why cannabinoids do not suppress breathing.[8][13] In 1992, the brain's own cannabinoid molecule — anandamide — was isolated, demonstrating that the body runs its own version of this system.[3]
Clinical development and regulation
Synthetic THC (dronabinol) received FDA approval for chemotherapy-induced nausea in 1985,[14] and nabiximols (Sativex), a THC:CBD oromucosal spray, was approved in Canada for multiple sclerosis spasticity in 2005.[15] Cannabis was placed in US Schedule I in 1970;[16] in April 2026, FDA-approved marijuana products were moved to Schedule III, with broader rescheduling pending.[4]
The word cannabis derives from Greek kannabis, likely borrowed from a Scythian or Central Asian root. THC's cultural reach spans Vedic ritual, Sufi mysticism, Caribbean Rastafarian practice, and the American counterculture of the 1960s.[12]
Chemistry[edit]
Structure and classification
THC belongs to the terpenophenolic structural class — a chemical family characteristic of the phytocannabinoids in Cannabis sativa. It is one of more than 100 phytocannabinoids identified in the plant,[17] structurally related to cannabidiol (CBD), cannabinol (CBN), and delta-8-THC. Its molecular formula is C₂₁H₃₀O₂ (molecular weight 314.5 g/mol).
Potency and natural occurrence
In the plant, THC exists as its inactive precursor THCA until heat — from smoking, vaporizing, or baking — converts it to the pharmacologically active delta-9-THC.[17] THC content ranges from less than 0.3% in hemp cultivars to over 25% in high-potency strains[17] — an 80-fold variation in potency. This matters clinically: daily use of high-potency cannabis (THC ≥10%) is strongly linked to elevated psychotic disorder risk.[10]
Pharmacology[edit]
Mechanism of action
THC is a partial agonist at CB1 cannabinoid receptors.[18] Partial agonism means its maximal effect is lower than synthetic full agonists — its ceiling depends on receptor availability and the brain's existing cannabinoid activity.[18] The net effect is suppression of neurotransmitter release at synapses throughout the brain, co-opting the retrograde endocannabinoid signalling system.[19]
Pharmacokinetics
The route of administration determines almost everything about how the experience unfolds.[9][20] Inhaled THC reaches the bloodstream within minutes, producing effects within seconds;[9] vaporization achieves higher bioavailability than smoking at equivalent doses.[21] Oral THC is absorbed poorly (4–20%), with onset delayed 30–90 minutes and peak effects at 2–3 hours — a significant safety risk, as users frequently redose before the first dose has taken full effect.[9]
Metabolism and elimination
The liver converts THC first to 11-hydroxy-THC (11-OH-THC), an active metabolite that is comparably potent and likely drives much of the oral experience, then to THC-COOH, the inactive compound detected in urine tests.[20][22] THC accumulates in fat tissue and clears slowly — terminal half-life runs 20–57 hours in occasional users, longer with chronic use.[9] THC-COOH can remain detectable in urine for days after a single use and weeks to months in heavy users.[9]
Neuroscience[edit]
Where it acts
The brain has its own cannabinoid signalling system. Under normal conditions, neurons produce endocannabinoids on demand to briefly dial down activity at neighboring synapses.[19] THC overrides this by persistently occupying CB1 receptors — imposing sustained suppression of both excitatory and inhibitory signalling, whether needed or not.[19]
The consequences follow the brain's receptor map[8]: dense CB1 receptors in the hippocampus produce acute memory suppression;[6] in the amygdala, modulation creates the biphasic anxiety pattern — low-dose calm, high-dose paranoia;[5] in the cerebellum and basal ganglia, motor coordination and executive function are impaired.[23][13]
Why it matters
The endocannabinoid system normally acts as a circuit breaker, preventing runaway excitation or inhibition across neural circuits.[19] THC disrupts that homeostasis — which is why its effects are so context-dependent. Tolerance builds to cognitive and anxiety effects but not to euphoria[24]: the reward response persists even as other effects fade, a pattern that drives compulsive use.[25]
Adolescent THC exposure in animal models produces lasting cognitive and behavioural changes,[26] but whether this reflects permanent damage or reversible adaptation is unresolved. Why some users develop persistent psychotic disorders while most experience only transient symptoms is poorly understood — genetic variants in AKT1 and COMT have been implicated, but no predictive marker exists.[27]
Subjective Effects[edit]
THC produces a subjective state with an unusually narrow margin between pleasant and overwhelming. At modest doses, time slows, appetite awakens, and sensory experience sharpens into something warmer and more engaging than usual. The shift between warm calm and anxious self-consciousness is rapid and unpredictable — the same dose in a different mood or setting can feel entirely different.[5]
Within the cannabinoid family, THC is far milder than the synthetic full agonists found in "spice" products, which produce a harsher and less predictable experience. Compared to classical psychedelics, THC produces little perceptual distortion and no ego dissolution at typical doses, but shares the capacity for dose-dependent paranoia at the upper range.[6]
Isolated by Gaoni and Mechoulam in 1964,[3] THC gave molecular identity to a plant used therapeutically for millennia. Its discovery triggered identification of the endocannabinoid system — the CB1 receptor,[4] anandamide[5] — revealing an entirely new signalling network in the mammalian brain. As of 2026, FDA-approved THC formulations sit in US Schedule III,[6] while recreational cannabis is legal in Canada, Germany, and numerous US states.
Subjective effects include euphoria, appetite stimulation, time alteration, relaxation, and anxiety at higher doses. The experience is defined by its sensitivity to context — the boundary between warm relaxation and anxious self-consciousness is narrow and unpredictable, modulated heavily by dose, tolerance, and psychological state.[7] Paranoia, short-term memory disruption, and transient psychotomimetic symptoms are characteristic unsought effects.[8]
THC produces moderate dependence — approximately 9% of users develop cannabis use disorder, rising to 17% with adolescent onset[9] — with no confirmed human fatality from overdose alone.[10][11] The primary risk is psychiatric: daily high-potency cannabis use carries an odds ratio of 4.8 for psychotic disorder,[12] compounding with early onset and genetic vulnerability. Six decades of clinical, epidemiological, and neuroimaging research make THC one of the most thoroughly characterized psychoactive compounds known.
History[edit]
Discovery
Cannabis sativa has been used as a medicine for millennia — documented in Vedic texts (~800 BCE), Chinese pharmacopoeia, and Egyptian medical papyri.[13][14] The identity of its principal psychoactive constituent eluded chemists until 1964, when Yechiel Gaoni and Raphael Mechoulam at the Weizmann Institute published the isolation, structural characterization, and partial synthesis of delta-9-tetrahydrocannabinol.[3] This single paper founded modern cannabinoid pharmacology.
The endocannabinoid system
THC's isolation set off one of the most productive research trajectories in neuroscience. In 1988, Devane and colleagues identified a specific cannabinoid binding site in rat brain, establishing what became the CB1.[4] Herkenham's 1990 mapping revealed dense receptor expression in the hippocampus, basal ganglia, cerebellum, and cortex — with sparse brainstem presence, directly explaining why cannabinoids do not suppress breathing.[10][15] In 1992, Mechoulam's group isolated anandamide from porcine brain, demonstrating that the body produces its own cannabinoid molecules.[5]
Clinical development and regulation
Dronabinol (synthetic THC) received FDA approval for chemotherapy-induced nausea in 1985,[16] with a second indication for AIDS-related anorexia in 1992. Nabiximols (Sativex), a THC:CBD oromucosal spray, was approved in Canada in 2005 for multiple sclerosis spasticity.[17] Cannabis was placed in US Schedule I in 1970;[18] in April 2026, the DOJ moved FDA-approved marijuana products to Schedule III, with broader rescheduling hearings pending.[6]
The word cannabis derives from Greek kannabis, likely borrowed from a Scythian or Central Asian root. THC's cultural reach spans Vedic ritual, Sufi mysticism, Caribbean Rastafarian practice, and the American counterculture of the 1960s.[14]
Chemistry[edit]
Structure and classification
THC belongs to the terpenophenolic structural class — a dibenzopyran (benzochromene) derivative characteristic of the phytocannabinoid family. The molecule consists of a tricyclic benzo[c]chromene core with a five-carbon (n-pentyl) side chain at C-3, a phenolic hydroxyl at C-1, and geminal dimethyl groups at C-6. The "Δ9" designation specifies the double bond between C-9 and C-10 in the terpenoid ring, distinguishing it from the less potent Δ8-THC isomer.
THC is one of more than 100 phytocannabinoids identified in Cannabis sativa.[19] Structurally related compounds include cannabidiol (CBD), cannabinol (CBN), and delta-8-THC, each differing in ring closure, oxidation state, or double-bond position.
| Molecular formula | C₂₁H₃₀O₂ |
| Molecular weight | 314.5 g/mol |
Biosynthesis
In the cannabis plant, THC is produced as its carboxylated precursor THCA. Olivetolic acid and geranyl pyrophosphate combine to form cannabigerolic acid (CBGA), which THCA synthase cyclizes to Δ9-tetrahydrocannabinolic acid. Thermal decarboxylation — smoking, vaporizing, or baking — converts THCA to the pharmacologically active Δ9-THC.[19]
Stereochemistry
THC has two chirality centres (positions 6a and 10a). The naturally occurring and pharmacologically active form is the (−)-''trans isomer, designated (6aR,10aR). The stereoselective nature of cannabinoid receptor binding — the (−)-trans configuration binds far more potently than the (+)-cis'' enantiomer — provided early evidence for the existence of a specific receptor.[4]
Stability and natural occurrence
Pure THC is a pale yellow viscous resinous oil, practically insoluble in water but highly lipophilic (logP ≈ 7).[11] It degrades on exposure to light, heat, and oxygen — primarily oxidizing to cannabinol (CBN), which has only weak receptor activity. Improperly stored cannabis loses potency over time as THC converts to less active degradation products.
THC content in plant material ranges from <0.3% in hemp cultivars to >25% in high-potency drug-type strains.[19] This >80-fold variation in potency is toxicologically significant: the epidemiological association between high-potency cannabis (THC ≥10%) and psychotic disorder risk is among the strongest findings in cannabis safety research.[12]
Pharmacology[edit]
Mechanism of action
THC is a partial agonist at both CB1 and CB2 cannabinoid receptors.[1] This partial agonism constrains its maximal effect: unlike synthetic full agonists such as CP-55,940 and HU-210, THC's response ceiling depends on how many receptors are available and the brain's ongoing endocannabinoid tone.[1] In tissues with low receptor density, THC can function as a competitive antagonist — occupying the binding site while producing minimal activation.
At the CB1 receptor, THC inhibits adenylate cyclase, modulates calcium and potassium channels, and activates MAPK signalling cascades.[2][20] The net synaptic effect is suppression of neurotransmitter release — both GABA and glutamate — at presynaptic terminals, co-opting the brain's retrograde endocannabinoid signalling mechanism.[2]
CB2 receptors, expressed 10–100-fold more highly in immune tissues than CB1 in the brain,[21] are presumed to mediate THC's immunomodulatory effects. Beyond the canonical cannabinoid receptors, THC activates TRPV1 channels and modulates GPR55,citation needed and induces dopamine release in the human striatum[22] — providing a neurochemical basis for its rewarding properties.
Pharmacokinetics
THC's pharmacokinetics are dominated by extreme lipophilicity and extensive liver metabolism.[11][23]
Inhalation delivers 10–35% of the dose to the bloodstream, with peak plasma levels within 3–10 minutes and effects felt within seconds.[11] Vaporization achieves higher bioavailability than smoking at equivalent doses.[24]
Oral bioavailability is substantially lower (4–20%) due to extensive first-pass liver metabolism. Onset is delayed 30–90 minutes, peak effects arrive at 2–3 hours, and total duration extends to 4–12 hours.[11] The delayed and unpredictable onset of oral cannabis is a significant safety concern — users frequently redose before the first dose has taken full effect.
Once absorbed, THC distributes widely (volume of distribution ~10 L/kg), is 97–99% protein-bound, and accumulates in fat, brain, and other lipid-rich tissues.[11] The liver converts THC first to 11-hydroxy-THC (11-OH-THC), an active metabolite with comparable psychoactive potency that may drive much of the oral experience, and then to THC-COOH, the inactive metabolite detected in urine drug tests.[23][25]
Elimination follows a biphasic pattern: an initial half-life of 1–3 hours, then a terminal half-life of 20–57 hours in occasional users — prolonged further in chronic users due to slow release from fat stores. THC-COOH remains detectable in urine for days to weeks after a single use, and weeks to months in heavy users.[11]
Neuroscience[edit]
Where it acts
THC hijacks the endocannabinoid retrograde signalling system. Under normal conditions, postsynaptic neurons produce endocannabinoids (anandamide, 2-AG) on demand to briefly suppress neurotransmitter release at presynaptic terminals.[2] THC overrides this fine-tuned feedback by persistently occupying CB1 receptors, imposing sustained, non-activity-dependent suppression of both excitatory and inhibitory transmission.[2]
The consequences map directly onto receptor distribution[10]: dense CB1 expression in the hippocampus produces acute short-term memory suppression;[8] in the amygdala, dose-dependent modulation generates the characteristic biphasic anxiety response — low-dose calm, high-dose paranoia;[7] in the cerebellum and basal ganglia, impaired motor coordination and executive function.[26][15]
Why it matters
The endocannabinoid system functions as a homeostatic "circuit breaker" — preventing runaway excitation or inhibition across neural circuits.[2] THC disrupts this homeostasis with sustained, non-contingent CB1 activation, which explains why its effects are so context-dependent: the same dose may relax a calm person or overwhelm someone already stressed.
A separate finding with implications for addiction: tolerance develops to THC's cognitive, psychotomimetic, and anxiety-producing effects, but not to its euphoric effects.[27] The mesolimbic dopamine system adapts less than cortical systems, meaning users continue to experience reward even as other effects fade — a pattern that drives compulsive use. THC-induced striatal dopamine release, while modest compared to stimulants,[22] sustains this reinforcement.
Adolescent THC exposure in animal models produces lasting cognitive and behavioural dysfunction,[28] but whether this reflects true neuroplastic damage or reversible adaptation is unresolved. The neural basis for individual vulnerability to THC-induced psychosis — why most users experience only transient symptoms while some develop persistent psychotic disorders — remains poorly understood; genetic variants in AKT1 and COMT have been implicated but no predictive biomarker exists.[29]
Subjective Effects[edit]
THC produces a subjective state defined by its sensitivity to context. At low doses the experience tends toward warm relaxation, heightened sensory engagement, and gentle euphoria; at moderate doses, time perception fractures, appetite intensifies, and thought patterns become looping or associative; at high doses, the warmth curdles into anxiety, paranoia, and transient psychotic-like symptoms.[7] Set, setting, tolerance, and route of administration modulate the outcome more than for most psychoactive compounds — the same person, at the same dose, may have starkly different experiences across contexts.
Within the cannabinoid class, THC is the prototypical partial agonist, producing a ceiling of effect that synthetic full agonists (JWH-018, CP-55,940) dramatically exceed in both intensity and risk. Compared to classical psychedelics, THC produces far less perceptual distortion and no ego dissolution at typical doses, but shares the capacity for dose-dependent anxiety and paranoia at the upper range.[8]
Effect Grid
A clear psychoactive state — the 'classic' cannabis experience for most users. Euphoria, sensory enhancement, appetite stimulation, and time distortion are all prominent. Music enhancement is often striking. Body heaviness or relaxation sets in, and laughter fits may occur spontaneously.
Short-term memory is noticeably impaired — conversations may lose their thread, and recent thoughts can slip away. Psychomotor performance is reduced. Heart rate increases and dry mouth is common. Anxiety may emerge in predisposed individuals or unfamiliar settings.
This is the dose range most users target for recreational or social use. Functional impairment is significant — driving, operating machinery, and complex decision-making are unsafe. Duration commitment is 2–3 hours inhaled, 4–8 hours oral.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Taste enhancement · Color alteration · Depth perception distortion · Perspective distortion · Sound sensitivity · Vestibular distortion · Auditory distortion · Auditory misinterpretation · Brightness alteration · Proprioceptive distortion · Touch enhancement · Olfactory enhancement · Visual processing suppression · Internal hallucinations · Auditory hallucinations · External hallucinations
Sound sensitivity · Vestibular distortion · Auditory distortion · Auditory misinterpretation · Brightness alteration · Proprioceptive distortion · Touch enhancement · Olfactory enhancement · Visual processing suppression · Internal hallucinations · Auditory hallucinations · External hallucinations
Laughter fits · Muscle relaxation · Pain suppression · Sedation · Appetite enhancement · Bodily heaviness · Dizziness · Nausea suppression · Physical fatigue · Body schema distortion · Breathing alteration · Tactile euphoria · Constipation · Insomnia · Nausea · Sexual arousal enhancement · Stimulation · Temperature dysregulation · Wakefulness · Muscle tension · Restlessness · Sexual arousal suppression · Vomiting · Bodily dissociation
Sedation · Appetite enhancement · Bodily heaviness · Dizziness · Nausea suppression · Physical fatigue · Body schema distortion · Breathing alteration · Tactile euphoria · Constipation · Insomnia · Nausea · Sexual arousal enhancement · Stimulation · Wakefulness · Muscle tension · Restlessness · Sexual arousal suppression · Vomiting · Bodily dissociation
Cognitive euphoria · Information processing suppression · Memory fragmentation · Thought connectivity · Thought disorganization · Humor enhancement · Focus suppression · Analysis suppression · Cognitive fatigue · Conceptual thinking · Confusion · Immersion enhancement · Novelty enhancement · Cognitive flexibility · Creativity enhancement · Introspection enhancement · Language suppression · Motivation suppression · Multiple thought streams · Openness enhancement · Suggestibility enhancement · Thought acceleration · Thought loops · Cognitive dysphoria · Pattern recognition enhancement · Thought deceleration · Analysis enhancement · Focus enhancement · Amnesia · Delirium · Delusions
Thought connectivity · Thought disorganization · Humor enhancement · Focus suppression · Analysis suppression · Cognitive fatigue · Conceptual thinking · Confusion · Immersion enhancement · Novelty enhancement · Cognitive flexibility · Creativity enhancement · Introspection enhancement · Language suppression · Motivation suppression · Multiple thought streams · Openness enhancement · Thought acceleration · Thought loops · Cognitive dysphoria · Pattern recognition enhancement · Thought deceleration · Analysis enhancement · Focus enhancement · Amnesia · Delirium · Delusions
Emotional enhancement · Dysphoria · Emotional lability · Irritability · Simultaneous emotions · Anhedonia · Mania
Irritability · Simultaneous emotions · Anhedonia
Disinhibition · Emotional susceptibility · Social connection · Communication enhancement · Communication suppression · Flow state · Sociability suppression · Social disconnection · Cognitive disconnection · Boundary dissolution
Communication suppression · Flow state · Sociability suppression · Social disconnection · Cognitive disconnection · Boundary dissolution
Timeline
Gradual awareness of psychoactive effects beginning 30–90 minutes after ingestion. Subtle mood shift and mild body sensations may be the first signs.
Slow intensification of effects. Users frequently misjudge timing and redose during this phase — this is the most common cause of accidental oral cannabis overdose.
Full expression of effects, often qualitatively heavier and more sedating than inhaled cannabis due to first-pass conversion to the active metabolite 11-OH-THC. Euphoria, deep body heaviness, pronounced time distortion, and significant cognitive impairment.
Sustained effects at or near peak intensity. Sedation and appetite stimulation are often dominant. Cognitive impairment remains significant.
Slow diminution of effects over several hours. Sedation may predominate as other effects fade. The prolonged offset is driven by slow redistribution of THC from adipose stores.
Residual fatigue, cognitive fog, and possible appetite changes lasting up to 24 hours. Mood may feel flat or mildly elevated.
⚠ Do not drive for at least 8 hours after oral cannabis consumption — the prolonged and unpredictable duration of edible cannabis effects makes driving assessment difficult.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 28 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- synthetic cannabinoids · endocannabinoids · other CB1 agonists
Toxicity
Acute toxicity
No confirmed human fatality from THC overdose alone has been recorded. Cannabinoid receptors are nearly absent from brainstem centres controlling breathing,[8] giving THC a therapeutic index exceeding 1000:1.[8][9]
Common acute adverse effects include rapid heartbeat,[28][6] dizziness from blood pressure drops,[28] anxiety and panic,[9][6] and at higher doses, hallucinations, paranoia, and blunted affect.[6] High-potency cannabis impairs executive function and motor control at common recreational doses.[23]
Heart and circulation
THC reliably raises heart rate and can lower blood pressure on standing. Tolerance to these effects develops with prolonged use.[28] Cannabis is contraindicated in individuals with significant heart conditions.[20]
Cannabinoid hyperemesis syndrome
Chronic heavy users can develop a paradoxical condition: cycles of severe nausea and vomiting, with a compulsive drive to bathe in hot water for relief.[29] Standard anti-nausea medications are ineffective. The condition appears to have become more common following cannabis legalization, and fatal complications have been reported.[30]
Respiratory effects (smoking route)
Chronic cannabis smoking causes chronic bronchitis symptoms — cough, sputum, and wheezing — and impairs immune function in the lungs. Unlike tobacco, cannabis smoking has not been consistently linked to emphysema or COPD.[31] Vaporization reduces but does not eliminate respiratory irritant exposure.
Pregnancy and breastfeeding
THC crosses the placenta and accumulates in breast milk.[32] Cannabis use during pregnancy is associated with lower birth weight and potential effects on the developing brain. Medical guidance from ACOG and AAP strongly advises against cannabis use during pregnancy or breastfeeding.[32]
Driving impairment
THC acutely impairs psychomotor performance relevant to driving. Blood THC levels correlate poorly with actual impairment, making legal limits based on blood concentration unreliable.[33]
Psychological risks
The association between cannabis and psychotic disorder is the most significant psychiatric safety concern. Daily cannabis use carries an odds ratio of 3.2 for psychotic disorder; daily high-potency use (THC ≥10%) raises this to 4.8.[10] THC is contraindicated in individuals with a personal or family history of psychotic disorders.[20]
Anxiety is the most common acute adverse psychological effect — low doses may calm, higher doses reliably produce anxiety and panic.[5] Adolescent cannabis use carries substantially higher psychiatric risk than adult-onset use.[27][26] Panic attacks are the most frequent adverse reaction prompting emergency department visits.[9]
Tolerance and dependence
Tolerance develops through CB1 desensitization, beginning within days of heavy regular use and reversing over roughly 2–4 weeks of abstinence.[34] Tolerance is selective: frequent users become tolerant to cognitive and anxiety-producing effects but not to euphoria.[24] This preserved reward response, as other effects fade, is significant for dependence risk.
About 9% of cannabis users develop cannabis use disorder, rising to 17% in those who begin in adolescence.[7] Cannabis withdrawal syndrome affects roughly 50% of regular users upon stopping[35]: irritability, insomnia, decreased appetite, restlessness, and depressed mood, with physical symptoms (sweating, tremors, abdominal pain) peaking at 2–3 days and resolving within 1–2 weeks.[34] No FDA-approved medication for cannabis use disorder exists.[36]
Drug Interactions
THC is metabolized primarily by liver enzymes CYP2C9 and CYP3A4. Both THC and CBD inhibit these same enzymes,[22] raising blood levels of other drugs processed through them — including warfarin, phenytoin, and many common medications. Chronic cannabis users may require higher doses of certain anaesthetics.[37]
CNS depressants — alcohol, benzodiazepines, opioids, and sedating antihistamines — add to THC's sedation and psychomotor impairment.[20] Stimulants add to increases in heart rate and blood pressure. THC may reduce the effectiveness of antipsychotics and worsen psychotic symptoms in people with schizophrenia spectrum disorders.
Contraindications
9 knownAbsolute:
- Active psychotic disorder or personal/family history of psychosis — the psychotomimetic effects[6] and strong association with psychosis incidence[10] make this the most critical contraindication.[20]
- Pregnancy and breastfeeding — THC crosses the placenta and accumulates in breast milk.[32]
Relative:
- Significant heart conditions — acute increases in heart rate and blood pressure drops may worsen pre-existing cardiac disease.[20]
- Lung disease — applies to combustion routes; vaporization or oral use may be considered with medical supervision.[31]
- Active substance use disorder — risk of complicating recovery.[27]
- Adolescence — elevated risk of lasting cognitive impairment and psychiatric vulnerability.[26][27]
- Driving or operating machinery while intoxicated — impairment cannot be reliably predicted from blood THC levels.[33]
- Liver impairment — THC is extensively liver-metabolized; reduced clearance may increase exposure.[20]
Harm Reduction[edit]
Forms & Identification
Cannabis products vary enormously in THC concentration — from less than 0.3% in hemp to over 25% in high-potency flower, and far higher in concentrates. A dose that produces mild relaxation with one product can trigger panic or psychotic symptoms with another.
Edibles require separate attention: onset is delayed 30–90 minutes, and the active metabolite 11-OH-THC produced during liver processing creates a qualitatively different, often more intense experience than inhaled cannabis.
Testing matters most for concentrates and edibles, where potency can vary dramatically between batches. In unregulated markets, cannabis vape cartridges have been found to contain contaminants including vitamin E acetate, heavy metals, and pesticides.
Guidelines
- Start low, go slow — particularly with edibles, where the delayed onset (30–90 minutes) frequently leads to premature redosing. Wait at least 2 hours before taking more.
- Know the product — potency varies enormously. A single inhalation of 25% THC flower delivers a fundamentally different dose than the same action with 10% flower.
- Inhale rather than ingest for first experiences — inhalation allows dose titration over minutes; oral cannabis commits to hours of effect from a single decision.
- Avoid daily high-potency use — the strongest safety signal in cannabis research links daily use of THC ≥10% products to psychotic disorder risk.
- Do not drive — THC impairs psychomotor performance and the degree of impairment cannot be predicted from how intoxicated a person feels.
- Avoid use before age 25 — adolescent and young adult brains are disproportionately vulnerable to THC's psychiatric and cognitive effects.
Set & Setting
THC's effects are unusually sensitive to psychological context. Anxiety, stress, or unfamiliar environments increase the likelihood of paranoia and panic, particularly at higher doses or for inexperienced users.
A comfortable, familiar setting with trusted people present substantially reduces the risk of an adverse psychological reaction. First-time users or those trying a new product should start in a low-stimulation environment where retreat is possible if needed.
Aftercare & integration. Most cannabis experiences resolve without aftercare needs. After an unexpectedly intense or distressing experience, basic recovery includes hydration, food, and sleep. The "cannabis hangover" — grogginess, mild cognitive fog, low motivation — typically clears within 24 hours.
For experiences involving severe anxiety or psychotic-like symptoms (paranoia, derealization, hallucinations), talking through the experience with a trusted person can help re-establish baseline perspective. If depersonalization, paranoia, or perceptual disturbances persist beyond 48 hours, professional evaluation is warranted — persistent symptoms may indicate vulnerability to cannabis-induced psychiatric conditions.
Recovery & Support
Cannabis use disorder affects approximately 9% of users and 17% of those who begin in adolescence.[7] Withdrawal — irritability, insomnia, appetite suppression, restlessness, depressed mood — peaks around day 2–3 and typically resolves within two weeks.[34]
No FDA-approved medication for cannabis use disorder exists.[36] Cognitive behavioural therapy (CBT) and motivational enhancement therapy (MET) are the best-supported treatment approaches. Marijuana Anonymous and SMART Recovery offer peer support structures.
For individuals whose use has become compulsive, the preserved euphoric response despite tolerance to other effects[24] is worth understanding — knowing why the drug remains rewarding even as its other effects fade can support the decision to stop.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most overwhelming cannabis experiences — racing heart, panic, paranoia, time alteration — are intensely unpleasant but not medically dangerous. Seek emergency help for: chest pain or pressure, fainting, seizures, inability to distinguish reality from hallucination, self-harm ideation, or persistent vomiting with dehydration.
Immediate steps:
- 1. Move the person to a quiet, comfortable space.
- 2. Reassure them: what they are experiencing is temporary and will pass.
- 3. If they are hyperventilating, guide slow breathing.
- 4. Offer water and light food if tolerated.
- 5. Do not give more cannabis, alcohol, or other substances.
- 6. If symptoms include chest pain, seizure, loss of consciousness, or active psychosis with self-harm risk, call emergency services immediately.
What to tell the dispatcher: The substance (cannabis/THC), approximate amount and route, time of use, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help.
Legal Status[edit]
Cannabis and THC occupy one of the most complex and rapidly evolving regulatory landscapes of any psychoactive substance.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Schedule I (CSA, 1970); FDA-approved THC products rescheduled to Schedule III (April 2026) | Cannabis in Schedule I since 1970.[16] FDA-approved marijuana products and state-licensed medical marijuana placed in Schedule III in April 2026; broader rescheduling hearing set for June 2026.[4] Hemp (<0.3% THC) exempt under 2018 Farm Bill. |
| Canada | Legal (recreational and medical) | Legal for adult use under the Cannabis Act (2018). Possession up to 30 g in public. |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | THC is Class B. CBD products limited to 1 mg THC per container. Sativex (nabiximols) is a Schedule 4 prescription medicine. |
| Germany | Legal (recreational, April 2024) | Recreational cannabis legalized for adults in April 2024. Possession up to 25 g; limited home cultivation.citation needed |
| Netherlands | Tolerated (gedoogbeleid) | Technically illegal but possession ≤5 g and coffee shop sales not prosecuted under the tolerance policy. |
| Australia | Prescription only (medical); prohibited (recreational) | Medical cannabis by TGA prescription for certain indications. No federal recreational legalization; some states have decriminalized possession. |
| New Zealand | Prescription only (medical); prohibited (recreational) | Medical cannabis legal with prescription. Recreational use illegal following the 2020 referendum. |
Legal status changes frequently. This page reflects the regulatory landscape as of 2026 and is not legal advice. Verify current rules in your jurisdiction before making decisions.
The 2018 US Farm Bill exempted hemp (<0.3% Δ9-THC by dry weight) from the Controlled Substances Act, inadvertently creating a regulatory grey area. This led to a proliferation of delta-8-THC and other minor cannabinoid products derived from hemp through chemical conversion. The regulatory status of these semi-synthetic cannabinoids remains contested across jurisdictions.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 28 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- synthetic cannabinoids · endocannabinoids · other CB1 agonists
Toxicity
Acute toxicity
No confirmed human fatality from THC overdose alone has been recorded. Cannabinoid receptors are nearly absent from brainstem centres controlling breathing and heart rhythm,[10] giving THC a therapeutic index exceeding 1000:1.[10][11]
Acute adverse effects are dose-dependent and include rapid heartbeat,[30][8] dizziness from blood pressure drops,[30] anxiety and panic reactions,[11][8] psychotic-like symptoms at higher doses (hallucinations, paranoia, blunted affect),[8] nausea (3.8%), dizziness (2.2%), and drowsiness (2.2%) in medical cannabis registry data.[31] High-potency cannabis produces measurable impairment of executive function and motor control at common recreational doses.[26]
Heart and circulation
THC reliably increases heart rate and can lower blood pressure on standing. Prolonged use produces tolerance to these cardiovascular effects.[30] Cannabis is contraindicated in individuals with significant heart conditions.[23]
Cannabinoid hyperemesis syndrome
Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition in chronic heavy users: cyclic severe nausea and vomiting with compulsive hot-water bathing for relief.[32] Standard anti-nausea medications are typically ineffective. CHS incidence appears to have risen following cannabis legalization, and fatal complications have been reported.[33]
Respiratory effects (smoking route)
Chronic cannabis smoking causes symptoms of chronic bronchitis — cough, sputum, wheezing — and impairs immune function in the lungs. Unlike tobacco, cannabis smoking has not been consistently linked to emphysema or COPD.[34] Vaporization reduces but does not eliminate respiratory irritant exposure.
Pregnancy and breastfeeding
THC crosses the placenta and accumulates in breast milk.[35] Cannabis use during pregnancy is associated with lower birth weight and potential neurodevelopmental effects in offspring. ACOG and AAP strongly advise against cannabis use during pregnancy and breastfeeding.[35]
Driving impairment
THC acutely impairs psychomotor performance relevant to driving. Blood THC levels correlate poorly with actual impairment, making legal limits based on blood concentration unreliable.[36]
Psychological risks
The association between cannabis and psychotic disorder is the most significant psychological safety concern. The EU-GEI study (901 first-episode psychosis cases, 1,237 controls across 11 European sites) found daily cannabis use conferred an odds ratio of 3.2 for psychotic disorder; daily use of high-potency cannabis (THC ≥10%) raised this to 4.8.[12] If high-potency cannabis were unavailable, an estimated 12.2% of first-episode psychosis cases would be preventable.
Controlled IV THC administration in healthy volunteers produces dose-dependent positive symptoms (hallucinations, paranoia) and negative symptoms (blunted affect, emotional withdrawal).[8] Adolescent cannabis exposure carries substantially higher psychiatric risk than adult-onset use.[29][28] THC is contraindicated in individuals with a personal or family history of psychotic disorders.[23]
Anxiety is the most common acute adverse psychological effect, following a bidirectional dose-response: low doses may calm, higher doses reliably produce anxiety.[7] Panic attacks are the most frequent adverse reaction prompting emergency department visits.[11]
Tolerance and dependence
Tolerance develops through CB1 desensitization and downregulation, beginning within days of regular heavy use and reversing over approximately 2–4 weeks of abstinence.[37]
Tolerance is differential: frequent users become tolerant to cognitive, psychotomimetic, and anxiety effects but not to euphoria.[27] This preserved reward response despite diminished other effects is significant for addiction risk.
Approximately 9% of cannabis users develop cannabis use disorder (CUD), rising to 17% among those beginning in adolescence.[9] Cannabis withdrawal syndrome affects approximately 50% of regular users upon cessation[38]: irritability, insomnia, decreased appetite, restlessness, depressed mood, and physical symptoms (sweating, tremors, abdominal pain). Onset occurs within 24–48 hours, peaks at 2–3 days, and resolves within 1–2 weeks.[37]
No FDA-approved medication for CUD exists.[39] Cross-tolerance occurs between THC and other CB1 agonists.
Drug Interactions
THC interacts with other substances through both metabolic and effect-based mechanisms.
THC is metabolized primarily by CYP2C9 and CYP3A4, and both THC and CBD inhibit these enzymes.[25] This can raise blood levels of co-administered drugs processed by these same pathways — a broad category including warfarin, phenytoin, and many common medications. Chronic cannabis users may require higher doses of certain anaesthetics.[40]
CNS depressants (alcohol, benzodiazepines, opioids, sedating antihistamines) produce additive sedation and psychomotor impairment when combined with THC.[23] Stimulants produce additive increases in heart rate and blood pressure. THC may reduce the effectiveness of antipsychotic medications and worsen psychotic symptoms in individuals with schizophrenia spectrum disorders. Anticholinergic drugs add to dry mouth, rapid heartbeat, and cognitive impairment.
Contraindications
9 knownAbsolute:
- Active psychotic disorder or personal/family history of psychosis — the dose-dependent psychotomimetic effects[8] and the strong association with psychosis incidence[12] make this the most critical contraindication.[23]
- Pregnancy and breastfeeding — THC crosses the placenta and accumulates in breast milk, with associated risks.[35]
Relative:
- Significant heart conditions — acute increases in heart rate and blood pressure drops may worsen pre-existing cardiac disease.[23]
- Lung disease — applies to combustion routes; vaporization or oral use may be considered with medical supervision.[34]
- Active substance use disorder — risk of complicating recovery.[29]
- Adolescence — elevated risk of lasting cognitive impairment and psychiatric vulnerability.[28][29]
- Driving or operating machinery while intoxicated — impairment cannot be reliably predicted from blood THC levels.[36]
- Liver impairment — THC is extensively liver-metabolized; reduced clearance may increase exposure.[23]
Harm Reduction[edit]
Forms & Identification
Cannabis products vary enormously in THC concentration — from <0.3% in hemp to >25% in high-potency flower and far higher in concentrates. This variation means a dose that produces mild relaxation with one product can trigger panic or psychotic symptoms with another. Edibles present an additional challenge: onset is delayed 30–90 minutes, and the active metabolite 11-OH-THC produced during liver processing creates a qualitatively different, often more intense experience than inhaled cannabis.
Testing matters most for concentrates and edibles, where potency can vary dramatically between batches. In unregulated markets, cannabis vape cartridges have been found to contain contaminants including vitamin E acetate, heavy metals, and pesticides.
Guidelines
- Start low, go slow — particularly with edibles, where the delayed onset (30–90 minutes) frequently leads to premature redosing. Wait at least 2 hours before taking more.
- Know your product — potency varies enormously. A single inhalation of 25% THC flower delivers a fundamentally different dose than the same action with 10% flower.
- Inhale rather than ingest for first experiences — inhalation allows dose titration over minutes; oral cannabis commits the user to hours of effect from a single decision.
- Avoid daily high-potency use — the strongest safety signal in cannabis research links daily use of THC ≥10% products to psychotic disorder risk.
- Do not drive — THC impairs psychomotor performance and the degree of impairment cannot be predicted from how intoxicated a person feels.
- Avoid use before age 25 — adolescent and young adult brains are disproportionately vulnerable to THC's psychiatric and cognitive effects.
Set & Setting
THC's effects are unusually sensitive to psychological context. Anxiety, stress, or unfamiliar environments increase the likelihood of paranoia and panic, particularly at higher doses or for inexperienced users. A comfortable, familiar setting with trusted people present substantially reduces the risk of an adverse psychological reaction. First-time users or those trying a new product should start in a low-stimulation environment where they can retreat if needed.
Aftercare & integration. Most cannabis experiences resolve without aftercare needs. After an unexpectedly intense or distressing experience, basic recovery includes hydration, food, and sleep. The "cannabis hangover" — grogginess, mild cognitive fog, low motivation — typically clears within 24 hours.
For experiences involving severe anxiety or psychotic-like symptoms (paranoia, derealization, hallucinations), talking through the experience with a trusted person can help re-establish baseline perspective. If depersonalization, paranoia, or perceptual disturbances persist beyond 48 hours, professional evaluation is warranted — persistent symptoms may indicate vulnerability to cannabis-induced psychiatric conditions.
Recovery & Support
Cannabis use disorder affects approximately 9% of users and 17% of those who begin in adolescence.[9] Withdrawal — irritability, insomnia, appetite suppression, restlessness, depressed mood — peaks around day 2–3 and typically resolves within two weeks.[37]
No FDA-approved medication for cannabis use disorder exists.[39] Cognitive behavioural therapy (CBT) and motivational enhancement therapy (MET) are the best-supported treatment approaches. Marijuana Anonymous and SMART Recovery offer peer support structures. For individuals whose use has become compulsive, the preserved euphoric response despite tolerance to other effects[27] is worth understanding — knowing why the drug remains rewarding even as its other effects fade can support the decision to stop.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most cannabis experiences that feel overwhelming — racing heart, panic, paranoia, time alteration — are intensely unpleasant but not medically dangerous. Seek emergency help for: chest pain or pressure, fainting, seizures, inability to distinguish reality from hallucination, self-harm ideation, or persistent vomiting with dehydration.
Immediate steps:
- 1. Move the person to a quiet, comfortable space.
- 2. Reassure them: what they are experiencing is temporary and will pass.
- 3. If they are hyperventilating, guide slow breathing.
- 4. Offer water and light food if tolerated.
- 5. Do not give more cannabis, alcohol, or other substances.
- 6. If symptoms include chest pain, seizure, loss of consciousness, or active psychosis with self-harm risk, call emergency services immediately.
What to tell the dispatcher: The substance (cannabis/THC), approximate amount and route, time of use, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help.
Legal Status[edit]
Cannabis and THC occupy one of the most complex and rapidly evolving regulatory landscapes of any psychoactive substance. At the international level, cannabis remains in Schedule I of the UN Single Convention on Narcotic Drugs (1961), though it was removed from the most restrictive Schedule IV in December 2020. Nationally, legal status ranges from full prohibition to regulated recreational access.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Schedule I (CSA, 1970); FDA-approved THC products rescheduled to Schedule III (April 2026) | Cannabis in Schedule I since 1970.[18] FDA-approved marijuana products and state-licensed medical marijuana placed in Schedule III in April 2026; broader rescheduling hearing set for June 2026.[6] Hemp (<0.3% THC) exempt under 2018 Farm Bill. |
| Canada | Legal (recreational and medical) | Legal for adult use under the Cannabis Act (2018). Possession up to 30 g in public. |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | THC is Class B. CBD products limited to 1 mg THC per container. Sativex (nabiximols) is a Schedule 4 prescription medicine. |
| Germany | Legal (recreational, April 2024) | Recreational cannabis legalized for adults in April 2024. Possession up to 25 g; limited home cultivation.citation needed |
| Netherlands | Tolerated (gedoogbeleid) | Technically illegal but possession ≤5 g and coffee shop sales not prosecuted under the tolerance policy. |
| Australia | Prescription only (medical); prohibited (recreational) | Medical cannabis by TGA prescription for certain indications. No federal recreational legalization; some states have decriminalized possession. |
| New Zealand | Prescription only (medical); prohibited (recreational) | Medical cannabis legal with prescription. Recreational use illegal following the 2020 referendum. |
The 2018 US Farm Bill exempted hemp (<0.3% Δ9-THC by dry weight) from the Controlled Substances Act, inadvertently creating a regulatory grey area. This led to a proliferation of delta-8-THC and other minor cannabinoid products derived from hemp through chemical conversion. The regulatory status of these semi-synthetic cannabinoids remains contested across jurisdictions.
Frequently asked questions
What is Tetrahydrocannabinol?
Tetrahydrocannabinol is the principal psychoactive cannabinoid in Cannabis sativa, acting as a partial agonist at CB1 and CB2 receptors. First isolated by Gaoni and Mechoulam in 1964, its discovery led to identification of the endocannabinoid system.
How long does Tetrahydrocannabinol last?
Total duration by route of administration — Smoked: 2 – 3 hours; Vaporized: 2 – 3 hours; Oral: 4 – 12 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Tetrahydrocannabinol?
Psychedex publishes a dosage table for Tetrahydrocannabinol on this page covering these routes of administration: smoked, vaporized, oral, intravenous. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Tetrahydrocannabinol?
The highest-severity documented interactions for Tetrahydrocannabinol: GHB, Baclofen (Dangerous), GHB, GBL (Dangerous), Ibogaine (Dangerous), Ketamine, DXM, PCP (Dangerous), Local anesthetics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Tetrahydrocannabinol addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Tetrahydrocannabinol: tolerance builds moderate; full reset takes 28 days; cross-tolerance develops with synthetic cannabinoids, endocannabinoids, other CB1 agonists. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abGaoni Y, Mechoulam R (1964) Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish — Journal of the American Chemical Society doi:10.1021/ja01062a046
- [2] ^abDevane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. — Molecular Pharmacology PMID:2848184
- [3] ^abDevane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. — Science PMID:1470919
- [4]
- [5] ^abcdCrippa JA, Zuardi AW, Martin-Santos R, Bhattacharyya S, Atakan Z, et al. (2009) Cannabis and anxiety: a critical review of the evidence — Human Psychopharmacology Clinical and Experimental doi:10.1002/hup.1048
- [6]
references
- [1] ^abcPertwee RG (2007) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin — British Journal of Pharmacology doi:10.1038/sj.bjp.0707442
- [2]
- [3] ^abGaoni Y, Mechoulam R (1964) Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish — Journal of the American Chemical Society doi:10.1021/ja01062a046
- [4] ^abcDevane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. — Molecular Pharmacology PMID:2848184
- [5] ^abDevane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. — Science PMID:1470919
- [6]